Cell Metabolism· Zhiguang Zhou, Xiaoxia Shi, Suyuan Jiang, Sihong Wang, Hongyan Shu, Wenli Sun, Haifang Wang, Li Cong, Li Mao, Liujun Fu, Shenglian Gan, Lili Zhang, Jie Han, Yunming Gao, Wei Wang, Lei Zhang, Fang Wang, Chuqing Cao, Xiang Yan, Haiyan Zhang, Tao Su, Wei Ling, Lasse Hjort Kyneb Jakobsen, Nicolas Belmar Nazal, Huiru Yan·· 19 小时前AI 评分49
新型GLP-1、GIP和胰高血糖素受体三重激动剂UBT251用于成人2型糖尿病：一项多中心随机II期临床试验
UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial
AI 导读
UBT251在成人2型糖尿病患者的多中心随机II期临床试验中，每周给药一次，至第24周HbA1c最多降低2.16%，体重最多降低9.8%。这一新型GLP-1/GIP/GCG受体三重激动剂总体耐受性良好，支持进一步开展III期评估。
来源：Cell Metabolism · cell.com